ODIN: Veterinary focus accelerates commercialization, with improved results and strong equity position
· Issued by Odinwell Ab
Revenue and operating loss both improved year-over-year as focus shifted to veterinary medicine, with novaQS product nearing market readiness and strong early demand. High equity ratio and ongoing financing initiatives support continued commercialization efforts.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
